论文部分内容阅读
目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者血清超氧化物歧化酶(superoxide dismutase,SOD)水平变化及临床意义。方法 DLBCL患者57例为观察组,同期淋巴结反应性增生患者40例为对照组,检测2组血清SOD水平并比较;分析DLBCL患者血清SOD水平与临床病理参数及化疗效果的关系。结果观察组血清SOD水平[(149.11±27.17)u/mL]明显低于对照组[(160.13±22.98)u/mL](P<0.05);不同年龄、性别DLBCL患者血清SOD水平比较差异无统计学意义(P>0.05),不同国际标准化预后指数(international prognostic index,IPI)评分、临床分期患者SOD水平比较差异有统计学意义(P<0.05);化疗2个疗程后完全缓解患者血清SOD水平[(158.74±29.49)u/mL]较化疗前[(149.11±27.17)u/mL]明显提高(P<0.05)。结论 DLBCL患者血清SOD水平降低,且其水平与IPI评分、临床分期、化疗效果有关;SOD可能参与了DLBCL的发病过程。
Objective To investigate the changes of serum superoxide dismutase (SOD) in patients with diffuse large B-cell lymphoma (DLBCL) and its clinical significance. Methods Fifty-seven patients with DLBCL were observed, and 40 patients with reactive lymph node hyperplasia during the same period were selected as the control group. The level of serum SOD was measured and compared between two groups. The relationship between serum SOD level and clinicopathological parameters and chemotherapeutic effect was analyzed. Results The level of serum SOD in the observation group was significantly lower than that in the control group [(149.11 ± 27.17) u / mL] (160.13 ± 22.98 u / mL, P <0.05) (P> 0.05). There was significant difference between different international prognostic index (IPI) scores and clinical stage SOD levels (P <0.05). The levels of serum SOD in patients with complete remission after 2 cycles of chemotherapy [(158.74 ± 29.49) u / mL] was significantly higher than that before chemotherapy [(149.11 ± 27.17) u / mL] (P <0.05). Conclusion Serum SOD level is decreased in patients with DLBCL, and its level is related to IPI score, clinical stage and chemotherapy effect. SOD may be involved in the pathogenesis of DLBCL.